4D Molecular Therapeutics Inc (FDMT)

$8.10 +0.20 (2.53%)
Market Cap 451.37M
Revenue (ttm) 40,000.00
Net Income (ttm) -160.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -402,175.00%
Debt to Equity Ratio 0.00
Volume 613,900
Avg Vol 1,037,720
Day's Range N/A - N/A
Shares Out 57.14M
Stochastic %K 10%
Beta 2.96
Analysts Strong Sell
Price Target $33.11

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degene...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 505 2680
Address:
5858 Horton Street, Suite 455, EmeryVille, United States
IPOPop
IPOPop Dec. 25 at 7:39 AM
$FDMT Upside depends on translating ambition into measurable cadence, where each milestone now functions as a credibility checkpoint. A coherent operating roadmap would be catalytic.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 24 at 10:40 PM
$FDMT Current Stock Price: $8.10 Contracts to trade: $10 FDMT Jan 16 2026 Call Entry: $0.32 Exit: $0.48 ROI: 51% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Emremumcu01
Emremumcu01 Dec. 24 at 12:24 AM
$RZLT $FDMT Merry christmas to all my longs
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 23 at 6:52 PM
$FDMT Hard to believe this was 11.50 a week ago.
2 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 23 at 6:30 PM
$FDMT Falling knife. Stay away until reversal is confirmed. This fell to a 100 MC within the last year. Who know how low this goes?
2 · Reply
senior_nurse
senior_nurse Dec. 23 at 5:33 PM
$FDMT caronte, drop the dark-pool fairy tales and Christmas squeeze fantasies. Shorts aren’t the story anymore — most likely already covered. What you’re seeing is regular traders exiting because it makes zero sense to park capital here with no real catalysts for a year+. Below $8 before Ded Moroz? It’s already there — and it’s not even Christmas. Meanwhile, there are actual setups like $ETON (Feb 25 PDUFA): enter ~2 months ahead, exit before the binary. You’ll thank me later for the tip.
0 · Reply
caronte
caronte Dec. 23 at 4:07 PM
$FDMT ask Dad Moroz to squeeze the shorts for Christmas.
0 · Reply
caronte
caronte Dec. 23 at 3:34 PM
$FDMT the shorts covered using dark pools? if they cover using the market this goes to 12+
0 · Reply
Emremumcu01
Emremumcu01 Dec. 23 at 3:21 PM
$FDMT shorts are having a field Day in here.
1 · Reply
Emremumcu01
Emremumcu01 Dec. 23 at 3:19 PM
$FDMT looking to re enter at 7$ this is getting destroyed
0 · Reply
Latest News on FDMT
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

Dec 17, 2025, 12:59 PM EST - 7 days ago

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Dec 17, 2025, 7:00 AM EST - 8 days ago

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

4DMT Announces New Employment Inducement Grants

Dec 12, 2025, 4:05 PM EST - 12 days ago

4DMT Announces New Employment Inducement Grants

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 8, 2025, 8:00 AM EST - 17 days ago

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 21, 2025, 7:43 PM EST - 4 weeks ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 5 weeks ago

4DMT to Participate in 8th Annual Evercore Healthcare Conference

4DMT Appoints Kristian Humer as Chief Financial Officer

Nov 17, 2025, 6:00 AM EST - 5 weeks ago

4DMT Appoints Kristian Humer as Chief Financial Officer

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 10, 2025, 8:00 AM EST - 6 weeks ago

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Jefferies 2025 London Healthcare Conference

Nov 6, 2025, 4:05 PM EST - 6 weeks ago

4DMT to Participate in Jefferies 2025 London Healthcare Conference

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Nov 6, 2025, 6:23 AM EST - 7 weeks ago

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

Nov 6, 2025, 6:00 AM EST - 7 weeks ago

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

Oct 30, 2025, 11:02 PM EDT - 7 weeks ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 14, 2025, 8:00 AM EDT - 2 months ago

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

Oct 13, 2025, 8:00 AM EDT - 2 months ago

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

Sep 30, 2025, 5:08 AM EDT - 3 months ago

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 6:13 PM EDT - 3 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Sep 2, 2025, 8:00 AM EDT - 4 months ago

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

4DMT to Participate in Upcoming Investor Conferences

Aug 25, 2025, 8:00 AM EDT - 4 months ago

4DMT to Participate in Upcoming Investor Conferences

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 11, 2025, 8:00 AM EDT - 4 months ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 8:00 AM EDT - 5 months ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Aug 1, 2025, 10:29 AM EDT - 5 months ago

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 31, 2025, 4:05 PM EDT - 5 months ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 24, 2025, 8:00 AM EDT - 5 months ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

Jul 2, 2025, 4:05 PM EDT - 6 months ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 8, 2025, 4:05 PM EDT - 8 months ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

May 1, 2025, 8:00 AM EDT - 8 months ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Mar 10, 2025, 8:00 AM EDT - 10 months ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 28, 2025, 4:05 PM EST - 10 months ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 18, 2025, 2:33 PM EST - 11 months ago

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Feb 10, 2025, 10:26 AM EST - 11 months ago

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Feb 8, 2025, 2:30 PM EST - 11 months ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 13, 2024, 4:05 PM EST - 1 year ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Nov 4, 2024, 11:00 AM EST - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Nov 2, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 30, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Oct 28, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Oct 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 12, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

Oct 10, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

IPOPop
IPOPop Dec. 25 at 7:39 AM
$FDMT Upside depends on translating ambition into measurable cadence, where each milestone now functions as a credibility checkpoint. A coherent operating roadmap would be catalytic.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 24 at 10:40 PM
$FDMT Current Stock Price: $8.10 Contracts to trade: $10 FDMT Jan 16 2026 Call Entry: $0.32 Exit: $0.48 ROI: 51% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Emremumcu01
Emremumcu01 Dec. 24 at 12:24 AM
$RZLT $FDMT Merry christmas to all my longs
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 23 at 6:52 PM
$FDMT Hard to believe this was 11.50 a week ago.
2 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 23 at 6:30 PM
$FDMT Falling knife. Stay away until reversal is confirmed. This fell to a 100 MC within the last year. Who know how low this goes?
2 · Reply
senior_nurse
senior_nurse Dec. 23 at 5:33 PM
$FDMT caronte, drop the dark-pool fairy tales and Christmas squeeze fantasies. Shorts aren’t the story anymore — most likely already covered. What you’re seeing is regular traders exiting because it makes zero sense to park capital here with no real catalysts for a year+. Below $8 before Ded Moroz? It’s already there — and it’s not even Christmas. Meanwhile, there are actual setups like $ETON (Feb 25 PDUFA): enter ~2 months ahead, exit before the binary. You’ll thank me later for the tip.
0 · Reply
caronte
caronte Dec. 23 at 4:07 PM
$FDMT ask Dad Moroz to squeeze the shorts for Christmas.
0 · Reply
caronte
caronte Dec. 23 at 3:34 PM
$FDMT the shorts covered using dark pools? if they cover using the market this goes to 12+
0 · Reply
Emremumcu01
Emremumcu01 Dec. 23 at 3:21 PM
$FDMT shorts are having a field Day in here.
1 · Reply
Emremumcu01
Emremumcu01 Dec. 23 at 3:19 PM
$FDMT looking to re enter at 7$ this is getting destroyed
0 · Reply
grizzly3
grizzly3 Dec. 23 at 3:12 PM
$FDMT The real catalyst clock is 2027: 4FRONT-1 topline in H1’27 and 4FRONT-2 52-wk topline in H2’27. Until then it’s mostly dead money + headline noise (yes, 4D-710 has a small H2’26 program update, but that’s not a “rerate-and-hold” event). Timing (not advice): if you must trade it, historically the better risk/reward is late 2026 (3–6 months before the H1’27 window) after the stock bases and the “time-to-catalyst” finally shrinks.
0 · Reply
Emremumcu01
Emremumcu01 Dec. 22 at 5:36 PM
$FDMT when’s a good time to come back in ?? I want some opinion’s from my mates on here. I’m hoping to get in around the 7.8 mark
2 · Reply
1iquid
1iquid Dec. 22 at 1:02 AM
💎 Liquid® Live Actionable Trade Asset: $FDMT Contracts: $FDMT July 17, 2026 $10 Calls Scale in: $2.33- $2.85 Scale out: $9.06-$15.53 Profit Potential : 91% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Emremumcu01
Emremumcu01 Dec. 20 at 10:55 PM
$FDMT guys I hate to say this because I love this stock but I sold my last shred last week . Il re enter when the time is right 👌been a crazy journey fellas
2 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 20 at 4:07 AM
$FDMT Somehow, 3.1M shares traded at market close without moving the price.
2 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 20 at 1:47 AM
$FDMT 4.3M in volume today? AH must have been busy.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 19 at 9:14 PM
$FDMT Good old Bizily selling what he is granted.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 19 at 8:56 PM
$FDMT And within minutes a .20 shed
2 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 19 at 8:55 PM
$FDMT A 9 break would be encouraging, but I think 9 is the new 12.
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 19 at 8:37 PM
Hedge Alert Live - Protect Your Portfolio Contract: $FDMT $7.50 Put · JAN 16, 2026 Exp Entry Price: $0.15 - $0.16 Exit Price Target: $0.26 Profit Margin: +71% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
ursus_horribilis
ursus_horribilis Dec. 19 at 8:00 PM
$FDMT Latest “updates” don’t change the setup: $100M offering priced at ~$10.51 = fresh dilution/overhang, and the 4D-710 CF Phase 1 interim data is nice headline fuel but not the kind of near-term catalyst that holds a tape. Evercore is just another short-lived splash. This still looks like a slow bleed back to reality — won’t be surprised to see it below $8 before New Year’s, and then it’s a long wait to matter again.
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Dec. 19 at 5:22 PM
$FDMT Needs to hold 8.50 or it levels down again.
0 · Reply